Pharmaceutical Technology on MSN
FDA halts uniQure’s plans for Huntington’s disease gene therapy
"FDA halts uniQure’s plans for Huntington’s disease gene therapy" was originally created and published by Pharmaceutical ...
UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...
Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...
However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...
Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment. Experts from University College London (UCL) said the finding could “change ...
Self Employed on MSN
FDA Feedback Surprises Huntington’s Drug Watchers
The post FDA Feedback Surprises Huntington’s Drug Watchers appeared first on Self Employed.
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's ...
Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients ...
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback